1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Takeda Pharmaceutical Company Limited
  6. Company
    4502   JP3463000004

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
Delayed Japan Exchange  -  02:00 2022-07-05 am EDT
3838.00 JPY   +0.68%
07/01Takeda's Takhzyro Shows 94.8% Reduction in Hereditary Angioedema Attacks in Phase 3 Trial in Children
MT
06/30TAKEDA PHARMACEUTICAL : Phase 3 SPRING study data presented at EAACI
PU
06/30Takeda's TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas:

- sale of drugs and consumer care products;

- services.

Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).

Number of employees : 47 347 people.
Sales per Business
20212022Delta
Gastroenterology777 800.0024.3%875 685.0024.5% +12.58%
Other574 068.0018%624 150.0017.5% +8.72%
Plasma-derived Therapies Immunology420 389.0013.1%506 951.0014.2% +20.59%
Neuroscience417 297.0013%482 294.0013.5% +15.58%
Oncology416 512.0013%468 730.0013.1% +12.54%
Rare Hematology289 799.009.1%283 689.008% -2.11%
Rare Metabolic162 620.005.1%172 595.004.8% +6.13%
Hereditary Angioedema139 327.004.4%153 587.004.3% +10.23%
JPY in Million
Sales per region
20212022Delta
United States1 567 930.0049%1 714 420.0048% +9.34%
Europe and Canada666 177.0020.8%739 168.0020.7% +10.96%
Japan559 748.0017.5%658 983.0018.5% +17.73%
Asia156 240.004.9%196 964.005.5% +26.07%
Latin America121 638.003.8%128 467.003.6% +5.61%
Other68 518.002.1%68 945.001.9% +0.62%
Russia / Commonwealth of Independent States57 560.001.8%62 057.001.7% +7.81%
JPY in Million
Managers
Name Title Age Since
Christophe Weber Chief Operating & Corporate Officer 55 2014
Constantine Saroukos Chief Financial Officer & Director 51 2019
Andrew Plump Director, Research & Development President 56 2019
Michael Mendelsohn Chief Medical & Scientific Officer 66 2015
Norimasa Takeda Chief Accounting Officer & Corporate Controller - -
Christopher David O'Reilly Global Head-Investor Relations - 2011
Satoru Takemoto General Manager-Sales - -
Masato Iwasaki, Dr. Manager-Product Strategy 63 2008
Mwana Lugogo Chief Ethics Officer - -
Giles Platford President-Europe & Canada - 2017
Members of the board
Name Title Age Since
Masahiro Sakane Independent Outside Director 81 2014
Shiro Kuniya Auditor 65 2013
Yoshiaki Fujimori Independent Director 69 2016
Emiko Higashi Independent Outside Director 62 2016
Michel Orsinger Independent Outside Director 64 2016
Toshiyuki Shiga Independent Outside Director 68 2016
Jean-Luc Butel Independent Outside Director 65 2016
Koji Hatsukawa Independent Outside Director 70 2016
Olivier Bohuon Independent Non-Executive Director 63 2019
Ian T. Clark Independent Director 60 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0.01 1,582,263,225 1,530,916,939 96.8% 31,891,746 2.0% 96.8%
Shareholders
NameEquities%
Nomura Asset Management Co., Ltd. 66,469,599 4.20%
BlackRock Fund Advisors 51,074,730 3.23%
The Vanguard Group, Inc. 39,413,933 2.49%
Nippon Life Insurance Co. 31,824,000 2.01%
Daiwa Asset Management Co. Ltd. 31,360,398 1.98%
Nikko Asset Management Co., Ltd. 31,068,898 1.96%
Takeda Pharmaceutical Company Limited 29,553,796 1.87%
Norges Bank Investment Management 23,314,335 1.47%
BlackRock Japan Co., Ltd. 23,218,800 1.47%
Takeda Science Foundation 17,912,000 1.13%
Holdings
NameEquities%Valuation
DENALI THERAPEUTICS INC. (DNLI) 4,214,559 3.43% 102,371,638 USD
DAY ONE BIOPHARMACEUTICALS, INC. (DAWN) 6,012,758 8.19% 37,399,355 USD
ASKA PHARMACEUTICAL HOLDINGS CO.,LTD. (4886) 2,204,000 7.21% 16,824,036 USD
OVID THERAPEUTICS INC. (OVID) 7,531,996 10.7% 12,729,073 USD
MIRUM PHARMACEUTICALS, INC. (MIRM) 530,562 1.67% 12,409,845 USD
HILLEVAX, INC. (HLVX) 840,500 2.65% 8,304,140 USD
CALITHERA BIOSCIENCES, INC. (CALA) 14,817,484 15.2% 3,037,584 USD
HOOKIPA PHARMA INC. (HOOK) 1,333,588 2.62% 2,293,771 USD
MOLECULAR TEMPLATES, INC. (MTEM) 2,314,659 4.11% 2,286,883 USD
WAVE LIFE SCIENCES LTD. (WVE) 1,096,892 1.79% 1,535,649 USD
Markets and indexes
- Prime
- Nikkei 225 / Stoxx Asia Pacific 50, Stoxx Global 200
Stock Exchange Codes
- Bloomberg Code :  4502:JP
- Reuters Code :  4502.T
- Datastream Code :  
Company contact information
Takeda Pharmaceutical Company Limited
1-1 Doshomachi 4-chome
JP-540-8645 Nishi-ku, Osaka

Phone : +81 6 6204 2111
Fax : +81 6 6204 2880
web site : http://www.takeda.co.jp
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED21.52%43 362
JOHNSON & JOHNSON4.94%472 389
PFIZER, INC.-11.41%293 506
ELI LILLY AND COMPANY17.55%292 291
ROCHE HOLDING AG-15.48%272 104
ABBVIE INC.13.59%271 782
NOVO NORDISK A/S6.75%248 942
MERCK & CO., INC.20.59%233 712
ASTRAZENECA PLC24.71%200 459
NOVARTIS AG0.06%181 232
BRISTOL-MYERS SQUIBB COMPANY23.24%163 597
AMGEN INC.9.15%131 173
SANOFI11.02%126 838
GSK PLC12.20%108 701
BAYER AG21.79%58 604
DAIICHI SANKYO CO., LTD.15.42%47 859
CHUGAI PHARMACEUTICAL CO., LTD-6.93%42 276
JIANGSU HENGRUI MEDICINE CO., LTD.-18.81%37 069
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD-19.15%31 582
ASTELLAS PHARMA INC.10.05%27 816
CATALENT, INC.-16.41%19 179